Patient Care: GLP-1 Mimetic Semaglutide Is Effective Across Ejection Fraction in Patients with HFpEF and Obesity: New STEP-HFpEF Analysis

Results from the prespecified analysis of STEP-HFpEF demonstrated that semaglutide, a glucagon-like peptide-1 (GLP-1) mimetic, improved scores on the Kansas City Cardiomyopathy Questionnaire Clinical Summary (KCCQ-CSS) and also led to reductions in body weight and systemic inflammation across LVEF categories in persons with the obesity phenotype of HFpEF.

The findings, wrote study authors in the Journal of the American College of Cardiology, support “the potential for use of semaglutide in patients with the obesity phenotype of HFpEF regardless of EF.” 

The study was led by renowned cardiologist Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, director of cardiometabolic research and codirector of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute.

Read the full Patient Care article: GLP-1 Mimetic Semaglutide Is Effective Across Ejection Fraction in Patients with HFpEF and Obesity: New STEP-HFpEF Analysis

Related Content

Aug. 28, 2023

New York Times: Obesity Treatment Relieves Heart Failure Symptoms, Drugmaker’s Study Finds
The drug Wegovy eased issues for people with a type of heart problem, adding to the treatment’s benefits beyond weight loss.
Aug. 25, 2023

MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Heart Failure
STEP-HFpEF trial findings were presented during the opening late breaking clinical trial session at the European Society of Cardiology Congress in Amsterdam, Netherlands.
Aug. 25, 2023

CNN: Weight-Loss Drug Wegovy Produces ‘Largest Benefit Ever Seen’ for Patients with Most Common Form of Heart Failure, Trial Finds
The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.